Traduction de «treat » (Français → Néerlandais) :

...prof manufacture of heat-treated foods 200 Chocoladebiscuit fats and oils for prof manufacture of heat-treated foods 200 Chocoprince fats and oils for prof manufacture of heat-treated foods 200 Frangipane fats and oils for prof manufacture of heat-treated foods 200 Doughnuts, ongevuld fats and oils for prof manufacture of heat-treated foods 200 Zandtaart fats and oils for prof manufacture of heat-treated foods 200 Taart, met creme au beurre fats and oils for prof manufacture of heat-treated foods 200 Frituurvet, 0-50 mg chol. frying oils, frying fats excl olive and pomace oils 200 Frituurvet, dierlijk en plantaardi frying oils, frying fats excl olive and pomace oils 200 Ozo vloeibaar frying oils, frying fats excl olive and pomace oils 200 Frituurvet Becel frying oils, frying fats excl olive and pomace oils 200 Olie, frituur- Becel frying oils, frying fats excl olive and pomace oils 200 Olie, frituur- VDM frying oils, frying fats excl olive and pomace oils 200 Rundvet, uitgesmolten lard, fish oil, beef, poultry, and sheep fat on fat content 200 Varkensvet, reuzel, uitgesmolten lard, fish oil, beef, poultry, and sheep fat on fat content 200 Volle melkpoeder milk powder for vending machine 200 Magere melkpoeder milk powder for vending machine 200 Pinda’s, gezouten processed nuts 200 Amandelen, gepeld processed nuts 200 Hazelnoten processed nuts 200 Paranoten processed nuts 200 Pinda’s, ongezouten processed nuts 200 Walnoten processed nuts 200 Noten, gemengd, ongezouten processed nuts 200 Borrelnoten, Calve processed nuts 200 Slasaus, 40% olie sauces 200 Yogonaise 25% olie, Calve sauces 200 Dressing 37% olie sauces 200 Saus, pakje, < 3% vet, bereid sauces 200 Saus, pakje, > 3% vet, bereid sauces 200 Tomatensaus, kant en klaar sauces 200 Barbecuesaus sauces 200 Cocktailsaus, 25% olie sauces 200 Tomatenketchup sauces 200 Fritessaus, 35% olie sauces 200 Schaschliksaus, Calve sauces 200 Kerriesaus, Calve sauces 200 Becel dressing, 50% olie sauces 200 Hotketchup, Heinz sauces 200 Curryketchup, Hei ...
...s for prof manufacture of heat-treated foods 200 Chocoprince fats and oils for prof manufacture of heat-treated foods 200 Frangipane fats and oils for prof manufacture of heat-treated foods 200 Doughnuts, ongevuld fats and oils for prof manufacture of heat-treated foods 200 Zandtaart fats and oils for prof manufacture of heat-treated foods 200 Taart, met creme au beurre fats and oils for prof manufacture of heat-treated foods 200 Frituurvet, 0-50 mg chol. frying oils, frying fats excl olive and pomace oils 200 Frituurvet, dierlijk en plantaardi frying oils, frying fats excl olive and pomace oils 200 Ozo vloeibaar frying oils, frying fats excl olive and pomace oils 200 Frituurvet Becel frying oils, frying fats excl olive and pomace oils 200 Olie, frituur- Becel frying oils, frying fats excl olive and pomace oils 200 Olie, frituur- VDM frying oils, frying fats excl olive and pomace oils 200 Rundvet, uitgesmolten lard, fish oil, beef, poultry, and sheep fat on fat content 200 Varkensvet, reuzel, uitgesmolten lard, fish oil, beef, poultry, and sheep fat on fat content 200 Volle melkpoeder milk powder for vending machine 200 Magere melkpoeder milk powder for vending machine 200 Pinda's, gezouten processed nuts 200 Amandelen, gepeld processed nuts 200 Hazelnoten processed nuts 200 Paranoten processed nuts 200 Pinda's, ongezouten processed nuts 200 Walnoten processed nuts 200 Noten, gemengd, ongezouten processed nuts 200 Borrelnoten, Calve processed nuts 200 Slasaus, 40% olie Sauces 200 Yogonaise 25% olie, Calve Sauces 200 Dressing 37% olie Sauces 200 Saus, pakje, < 3% vet, bereid Sauces 200 Saus, pakje, > 3% vet, bereid Sauces 200 Tomatensaus, kant en klaar Sauces 200 Barbecuesaus Sauces 200 Cocktailsaus, 25% olie Sauces 200 Tomatenketchup Sauces 200 Fritessaus, 35% olie Sauces 200 Schaschliksaus, Calve Sauces 200 Kerriesaus, Calve Sauces 200 Becel dressing, 50% olie Sauces 200 Hotketchup, Heinz Sauces 200 Curryketchup, Heinz Sauces 200 Frikandelsaus, 15% olie Sauces 200 Mayonaise, 80% olie Sau ...

Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

‐ Snyder E, McCullough J, Slichter S, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.

the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
‐ The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.

La décision de transfuser ou non ne pouvant être imposée par un processus d’attribution, une étude prospective sera confrontée au sort statistique à réserver aux patients non transfusés: sortie de l’étude et création d’un biais au moins théorique, ou respect du principe de l’intention to treat avec réduction corrélée des odds ratios. ▪ Les études portant sur les lésions de stockage constituent en quelque sorte un sousgroupe des études générales sur les effets de la transfusion, il est donc attendu que la valeur statistique des résultats obtenus ne soit guère éloignée à protocole comparable.
Daarom kampt een prospectieve studie met het statistisch lot voor te behouden voor niet-getransfundeerde patiënten: het uitvallen uit de studie en ontstaan van een minstens theoretische bias of naleven van het principe van intention to treat met gecorreleerde reductie van odds ratios. ▪ De studies inzake storage lesion vormen in zekere zin een subgroep bij de algemene studies over transfusie-effecten, het valt dus te verwachten dat de statistische waarde van de resultaten niet echt zullen verschillen bij toepassing van een gelijkaardig protocol.

Turkoski BB Treating clients with a deadly poison.
Turkoski BB. Treating clients with a deadly poison.

Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium).
Dierckx, K. Casier, E. De Baere, L. De Ridder, C. De Sadeleer, H. De Winter, M. Lippens, S. Van Imschoot, D. Wulfrank, M. Simons. Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium).

In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 22 .
In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 21 .

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Effective doses in families of 131 I-treated patients and ICRP-60 guidelines.
Effective doses in families of 131I-treated patients and ICRP-60 guidelines.